Russo, Pierluigi http://orcid.org/0000-0003-4881-5703
Zanuzzi, Matteo
Carletto, Angelica
Sammarco, Annalisa
Romano, Federica
Manca, Andrea
Article History
Accepted: 26 October 2022
First Online: 25 November 2022
Declarations
:
: The authors declare they have no financial interests.
: PR is head of the Health Economic Evaluation Unit at AIFA. MZ, AC, AS and FR are employees of the Health Economic Evaluation Unit at AIFA.
: This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. The views expressed in this work are personal and may not be understood or quoted as being made on behalf of or reflecting the position of the Italian Medicines Agency or of one of their committees or working parties, as well as of the other institutions involved.
: The dataset generated during the current study is not publicly available since all content of the pricing and reimbursement dossiers submitted to AIFA by pharmaceutical companies is reserved, except those data publicly available from other sources; moreover, net medicine prices are also confidential as they are covered by non-disclosure agreements between AIFA and pharmaceutical companies. Further information about the data used in this study are available from the corresponding author on reasonable request.
: All authors contributed to the study conception and design. Material preparation and data collection were performed by Matteo Zanuzzi, Annalisa Sammarco and Federica Romano. Statistical analyses were performed by Pierluigi Russo and Matteo Zanuzzi. The first draft of the manuscript was written by Pierluigi Russo and Angelica Carletto and all authors commented on previous versions of the manuscript. The supervision of the work was done by Andrea Manca. All authors read and approved the final manuscript. Confidential data considered in the analysis were managed by the co-authors employed at AIFA (PR, MZ, AC, AS, FR).